Immunosuppression and neoplasia. II. Is deficient immunesurveillance the only mechanism by which immunosuppression promotes neoplasia? A speculative review.
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D000961:Antilymphocyte Serum / Q000009:adverse effects; D000963:Antimetabolites / Q000008:administration & dosage / Q000009:adverse effects; D001379:Azathioprine / Q000009:adverse effects; D002273:Carcinogens / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D006087:Graft vs Host Reaction; D006649:Histocompatibility Antigens; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008223:Lymphoma / Q000276:immunology*; D015122:Mercaptopurine / Q000009:adverse effects; D051379:Mice; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB; D009858:Oncogenic Viruses / Q000276:immunology; D011344:Procarbazine / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000139:chemically induced; D013934:Thymectomy
D000961:Antilymphocyte Serum; D000963:Antimetabolites; D002273:Carcinogens; D006649:Histocompatibility Antigens; D007166:Immunosuppressive Agents; D011344:Procarbazine; D015122:Mercaptopurine; D001379:Azathioprine